Clinical Trials: Page 7
-
Courtesy of AbbVie
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.
By Jacob Bell • Nov. 11, 2024 -
Shutterstock/Ad_hominem
Sponsored by LabConnect7 steps to selecting the right global central lab
Unlock global clinical trial success with seamless sample logistics and standardized testing.
Nov. 11, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Peddalanka Ramesh Babu via Getty Images
Cancer cell therapy from Arcellx, Gilead shows promise in early data
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs compare.
By Jonathan Gardner • Nov. 5, 2024 -
Michael M. Santiago via Getty Images
Viking data provide latest test of oral obesity drug potential
Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the company still slipped.
By Ned Pagliarulo • Nov. 4, 2024 -
sanjeri via Getty Images
Sponsored by CognizantCenters of excellence or product-centric BizDevOps managed services?
As novel therapeutics become more complex — and costly — to bring to market, drug developers are looking to unified clinical development platforms to streamline operations.
Nov. 4, 2024 -
Rasi Bhadramani via Getty Images
Novo, with new results, to seek approval for obesity drug in MASH
The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm GLP-1s aren't a "silver bullet" for MASH, one analyst argued.
By Ben Fidler • Nov. 1, 2024 -
Dr_Microbe via Getty Images
New Alzheimer's drugsRoche weighs whether speedy approval path is open for latest Alzheimer’s drug
In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can significantly lower levels of amyloid in a Phase 3 trial.
By Jonathan Gardner • Oct. 31, 2024 -
Teemu Tretjakov/Adobe Stock and Edited by: TriNetX
Sponsored by TriNetXWith new diversity guidance, EHR data plus AI will be critical
With the new clinical trial diversity guidelines, the combination of EHR data and AI will be essential.
Oct. 28, 2024 -
Adobe Stock/# 501471652, by Puwasit Inyavileart
Sponsored by LabConnectDon’t let your samples slip: Why every clinical trial needs biospecimen management
Assure the integrity and efficiency of your clinical trials with support from a Biospecimen Manager.
Oct. 28, 2024 -
del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.
Intellia data spark debate about CRISPR drug’s potential
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't silence questions about its commercial outlook.
By Kristin Jensen • Oct. 24, 2024 -
iStock via Getty Images
Alto hits new low as depression drug flunks key test
While analysts still see value in Alto’s approach to brain drugmaking, investors may have lost some faith, as the biotech’s shares were down by two-thirds Wednesday morning.
By Jacob Bell • Oct. 23, 2024 -
Jian Fan via Getty Images
Otsuka’s startup bet pays off with kidney disease drug results
A medicine the pharma acquired in a 2018 buyout of Visterra succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.
By Ben Fidler • Oct. 22, 2024 -
Courtesy of Novo Nordisk
Oral version of Novo diabetes drug protects heart health in large study
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.
By Jonathan Gardner • Oct. 21, 2024 -
FatCamera via Getty Images
Sponsored by AltasciencesPharmaceutical research on mRNA and CAR T-cell therapy in cancer: Pioneering the future of oncology
Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?
Oct. 21, 2024 -
Kena Betancur via Getty Images
Merck antibody reduces RSV-related disease, hospitalizations in trial
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.
By Delilah Alvarado • Oct. 18, 2024 -
Carsten Koall via Getty Images
FDA puts Novavax flu vaccine trials on hold
The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.
By Delilah Alvarado • Oct. 16, 2024 -
Christoph Burgstedt via Getty Images
Wave sees RNA editing validation in early trial results
The data provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
By Ben Fidler , Ned Pagliarulo • Oct. 16, 2024 -
Warren Little via Getty Images
GSK says antibody drug succeeds in testing for chronic nasal condition
The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.
By Delilah Alvarado • Oct. 14, 2024 -
sanjeri via Getty Images
Sponsored by PearsonSuccessful COA selection paves the path to drug development
Choosing the right clinical outcome assessments (COAs) is an important part of successfully advancing drug development and securing regulatory approval.
Oct. 14, 2024 -
Wasan Tita via Getty Images
Sponsored by Thermo Fisher ScientificFrom maximizing recruitment to promoting diversity: How to deploy NGS technologies to achieve clinical trial success
Learn how the right NGS technology can enhance clinical research while supporting downstream efforts toward global commercialization.
Oct. 14, 2024 -
Scott Olson via Getty Images
Obesity drugsDrugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
Amgen’s MariTide readout Tuesday was the first domino to fall in a series of data readouts that could reshape expectations for the weight loss drug market.
By Jonathan Gardner • Updated Nov. 26, 2024 -
noparrit via Getty Images
Sage continues downslide as Alzheimer’s study fails
After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.
By Jacob Bell • Oct. 8, 2024 -
Stock via Getty Images
Scholar Rock scores with ‘surprise’ success in SMA drug study
Phase 3 findings could position the biotech’s therapy to become part of a “new standard” for SMA, its CEO said, while boosting research into whether it can preserve muscle in people with obesity.
By Ben Fidler • Oct. 7, 2024 -
Permission granted by MilliporeSigma
Sponsored by MilliporeSigmaAn effective analytical testing strategy for viral vectors should include these 7 steps
Producing safe, effective, high-quality viral vector therapeutics depends on a robust and tailored analytical testing strategy.
Oct. 7, 2024 -
AdobeStock/Rostislav Sedlacek
Sponsored by Advanced ClinicalBest practices for developing safety profiles in rare disease trials
The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.
By David Turner, Senior Director of Global Safety Services • Oct. 7, 2024
Previous
